Developing innovative and sustainable wound care technology, with marine ingredients from the coast of Norway

Regenics AS is a private Norwegian biotechnology company based in Oslo. The company develops a range of wound care products, with a current pipeline of two medical devices and one novel drug.

Target diagnoses and applications include burns, diabetic wounds, chronic wounds, and enzymatic wound debridement. One of our major innovations, HTX™, is a bioactive substance sourced and purified from unfertilized salmon roe.
With the unique healing qualities of unfertilized salmon roe, trout roe enzymes and other natural, marine ingredients, we aim to redefine current standards of care in wound management. We reduce waste in the aquaculture industry, and sustainability is at the core of everything we do.
ABOUT REGENICS
Collex® is a unique, 3D printed, advanced wound dressing containing HTX™ from salmon roe. Collex® is intended to aid healing of partial thickness burns and chronic wounds, and is currently in pre-clinical development.
Vernex® is an HTX™-based hydrogel wound spray, intended for treatment of partial thickness burns and chronic wounds. Vernex® is currently in pre-clinical development.
WoundClear™ is a novel investigational drug derived from trout LCE, intended for enzymatic wound debridement. WoundClear™ is currently in the discovery stage.
Our products
Pipeline
REG212
Wound healing
HTX from salmon roe• Advanced wound dressing• Medical device class III
Feasibility
Pre-Clinical
Pivotal
Discovery
REG320
Wound healing
HTX from salmon roe • Hydrogel wound spray• Medical device class III
Feasibility
Pre-Clinical
Pivotal
Discovery
REG410
Wound healing
LCE from trout • Enzymatic debridement• Novel drug
Phase 1
Discovery
Phase 2
Phase 3
Pre-Clinical
News
    Team
    Management
    Board
    • Jan Alfheim
      Chairman of the Board
    • Runhild Gammelsæter
      Board Member
    • Tore Heldrup Rasmussen
      Board member
    • Harald Nordal
      Board Member
    Team
    Partners